Breaking News
Investing Pro 0
💎 Access the Market Tools Trusted by Thousands of Investors Get Started
Close

Altimmune Inc (3G0)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.349 -0.005    -0.21%
29/09 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US02155H2004 
S/N:  A2N5Z6
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.326 - 2.349
Altimmune 2.349 -0.005 -0.21%

Altimmune Inc Company Profile

 
Get an in-depth profile of Altimmune Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

52

Equity Type

ORD

Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and is in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany Spain and Thailand. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Contact Information

Address 910 Clopper Road Suite 201S
Gaithersburg, 20878
United States
Phone 240 654 1450
Fax -

Top Executives

Name Age Since Title
Wayne F. Pisano 66 2018 Independent Director
David J. Drutz 82 2011 Independent Director
Mitchel B. Sayare 73 2010 Independent Chairman
John Petricciani 85 - Member of Scientific Advisory Board
Diane Kathryn Jorkasky 69 2020 Independent Director
Richard James Whitley 75 - Member of Scientific Advisory Board
Philip L. Hodges 52 2017 Independent Director
Klaus O. Schafer 71 2012 Independent Director
John M. Gill 69 2004 Independent Director
Vipin K. Garg 63 2018 President, CEO & Director
Naga Chalasani - 2022 Member of Nash Scientific Advisory Board
Daniel J. Drucker - 2022 Member of Obesity Scientific Advisory Board
Samuel Klein - 2022 Member of Obesity Scientific Advisory Board
Mazen Noureddin - 2022 Member of Nash Scientific Advisory Board
Donna Ryan - 2022 Member of Obesity Scientific Advisory Board
Caroline M. Apovian - 2022 Member of Obesity Scientific Advisory Board
Louis J. Aronne 66 2022 Member of Obesity Scientific Advisory Board
Juan Pablo Frias - 2022 Member of Obesity Scientific Advisory Board
Stephen A. Harrison - 2022 Member of Nash Scientific Advisory Board
Michael Charlton - 2022 Member of Nash Scientific Advisory Board
Robert F. Kushner - 2022 Member of Obesity Scientific Advisory Board
Rohit Loomba - 2022 Member of Nash Scientific Advisory Board
John M. Amatruda 77 2022 Member of Obesity Scientific Advisory Board
Catherine Angell Sohn 70 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALT Comments

Write your thoughts about Altimmune Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
vani vemula
vani vemula Mar 29, 2023 10:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any news?
Giuseppe Giannachi
Giuseppe Giannachi Mar 21, 2023 2:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Clinical trials and results seem very positive but the stock is tanking. Help me... cheers.
Giuseppe Giannachi
Giuseppe Giannachi Sep 14, 2022 12:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone around?
Jack Nicholson
Jack Nicholson Aug 12, 2021 12:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I've seen this one before, it looks like a come back but when I buy it, it goes down to a dollar. I'm not buying it though so it will probably do great ;o)
Ken Burian
Ken Burian Aug 12, 2021 12:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
lol. i would recommend you buy the stock and put in a stop loss to limit the potential damage for a speculative stock like this. i believed in this comeback early, so i bought in a month ago at 9. its been a nice run. i am now expecting a little pause, so i may sell some short term calls to take in a little profit.
Dirar Haddadin
Dirar Haddadin Aug 12, 2021 10:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What is the sxpectations ?
Zoran Labus
Zoran Labus Mar 26, 2021 7:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
alan abbas
alan abbas Feb 18, 2021 10:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
check out RIGL
Johnny Walker
Johnny Walker Feb 17, 2021 8:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
28?
Lucas Ang
Lucas Ang Feb 12, 2021 4:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great stock
Mohmoh lolkk
Mohmoh lolkk Dec 18, 2020 10:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
20.000plz
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email